Vaccination with a latch peptide provides serotypeindependent protection against group B streptococcus infection in mice

Shun Mei Lin, A. Yeung Jang, Yong Zhi, Shuang Gao, Sangyong Lim, Jae Hyang Lim, Joon Young Song, Paul M. Sullam, Joon Haeng Rhee, Ho Seong Seo

    Research output: Contribution to journalArticlepeer-review

    10 Citations (Scopus)

    Abstract

    Streptococcus agalactiae (group B streptococcus [GBS]) is a leading cause of invasive diseases in neonates and severe infections in elderly individuals. GBS serine-rich repeat glycoprotein 1 (Srr1) acts as a critical virulence factor by facilitating GBS invasion into the central nervous system through interaction with the fbrinogen Aa chain. This study revealed that srr1 is highly conserved, with 86.7% of GBS clinical isolates expressing the protein. Vaccination of mice with different Srr1 truncated peptides revealed that only Srr1 truncates containing the latch domain protected against GBS meningiThis. Furthermore, the latch peptide alone was immunogenic and elicited protective antibodies, which efciently enhanced antibody-mediated opsonophagocytic killing of GBS by HL60 cells and provided heterogeneous protection against 4 different GBS serogroups. Taken together, these fndings indicated that the latch domain of Srr1 may constitute an effective peptide vaccine candidate for GBS.

    Original languageEnglish
    Pages (from-to)93-102
    Number of pages10
    JournalJournal of Infectious Diseases
    Volume217
    Issue number1
    DOIs
    Publication statusPublished - 2018 Jan 1

    Keywords

    • Latch
    • Serine-rich repeat
    • Streptococcus agalactiae
    • Vaccine

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Infectious Diseases

    Fingerprint

    Dive into the research topics of 'Vaccination with a latch peptide provides serotypeindependent protection against group B streptococcus infection in mice'. Together they form a unique fingerprint.

    Cite this